Professor Copeland has been appointed Executive Director (ED) of IMCB from 5 November 2007. He joined IMCB in 2006 after spending more than 30 years in leading laboratories in the United States, including an illustrious 20-year career at the National Cancer Institute of the NIH (National Institutes of Health). He is ranked among the world’s top 50 most-cited biomedical scientists and has published more than 750 papers and has been cited more than 30,000 times. His pioneering work on discovering a way to accelerate the identification of cancer-causing genes in mice, which he did together with his wife, Professor Nancy Jenkins, Deputy Director IMCB.
Professor Copeland will build on the strong foundation and deep scientific capabilities at the IMCB, which marks its 20th anniversary this year. The institute was set up in 1987 as Singapore’s first foray into life sciences research with just 12 research staff and 24 graduate students. IMCB now has a strength of more than 400 research staff running 40 laboratories in the areas of cell and developmental biology, cancer genetics and translational research. IMCB also has core strengths in cell cycling, cell signalling, cell death, cell motility and protein trafficking. IMCB scientists have published over 1500 research papers in top international journals in the last 20 years.
Professor Copeland takes over from Professor Sir David Lane, who served as Chairman of IMCB’s Scientific Advisory Board from 2002 and as IMCB Executive Director (ED) since August 2004. Professor Lane holds a concurrent appointment at the University of Dundee in Scotland. Professor Copeland said, "It's a privilege for me to carry the baton of Singapore's oldest biomedical research institute. I intend to work with my colleagues to build on the initiatives David started to integrate and translate IMCB's solid scientific work into clinical applications. In particular, we will strengthen disease-focused research in areas such as cancer, inflammatory diseases and cardiovascular disease and further establish our expertise in animal models to better understand human diseases. We will underpin these translational efforts with basic scientific research of the highest standards and on developing and attracting the best scientific talent as the bedrock of IMCB."
For more information, click here to read the full press release.